Oncotarget

Research Papers:

A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-κB regulates head and neck squamous cell carcinoma proliferation

Zhipeng Li, Zejia Yang, Antonino Passaniti, Rena G. Lapidus, Xuefeng Liu, Kevin J. Cullen and Han C. Dan _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:31892-31906. https://doi.org/10.18632/oncotarget.7441

Metrics: PDF 2371 views  |   HTML 3326 views  |   ?  


Abstract

Zhipeng Li1, Zejia Yang1, Antonino Passaniti1,2, Rena G. Lapidus1, Xuefeng Liu3, Kevin J. Cullen1, Han C. Dan1,2

1The Marlene & Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA

2Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA

3Department of Pathology, Georgetown University Medical Center, Washington, DC, USA

Correspondence to:

Han C. Dan, email: HDan@som.umaryland.edu

Keywords: head and neck cancer, IKK, NF-kappaB, mTOR, Akt

Received: October 15, 2015     Accepted: February 05, 2016     Published: February 17, 2016

ABSTRACT

The overexpression or mutation of epidermal growth factor receptor (EGFR) has been associated with a number of cancers, including head and neck squamous cell carcinoma (HNSCC). Increasing evidence indicates that both the phosphatidylinositol-3-kinase (PI3K)-Akt-mammalian target of Rapamycin (mTOR) and the nuclear factor-kappa B (NF-κB) are constitutively active and contribute to aggressive HNSCC downstream of EGFR. However, whether these two oncogenic signaling pathways exhibit molecular and functional crosstalk in HNSCC is unclear. Our results now reveal that mTORC1, not mTORC2, contributes to NF-κB activation downstream of EGFR/PI3K/Akt signaling. Mechanistically, mTORC1 enhances the inhibitor of nuclear factor kappa-B kinase (IKK) activity to accelerate NF-κB signaling. Concomitantly, activated NF-κB/IKK up-regulates EGFR expression through positive feedback regulation. Blockage of NF-κB/IKK activity by the novel IKKβ specific inhibitor, CmpdA, leads to significant inhibition of cell proliferation and induction of apoptosis. CmpdA also sensitizes intrinsic cisplatin-resistant HNSCC cells to cisplatin treatment. Our findings reveal a new mechanism by which EGFR/PI3K/Akt/mTOR signaling promotes head and neck cancer progression and underscores the need for developing a therapeutic strategy for targeting IKK/NF-κB either as a single agent or in combination with cisplatin in head and neck cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 7441